ASH 2022: Promising Results in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma
The MonumenTAL-1, MajesTEC-2, OPTIMUM/MUKnine, and GMMG-CONCEPT trials have shown promising results for patients with newly diagnosed or relapsed/refractory multiple myeloma.
